Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer - Reply

被引：1
|
作者：
Sabbatini, Paul
Odunsi, Kunle
机构：
[1] Mem Sloan Kettering Canc Ctr, Gynecol Med Oncol Serv, New York, NY 10021 USA
[2] Roswell Pk Canc Inst, Div Gynecol Oncol, Buffalo, NY 14263 USA
来源：
CLINICAL CANCER RESEARCH | 2007年 / 13卷 / 13期
关键词：
D O I：
10.1158/1078-0432.CCR-07-0718
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4026 / 4027
页数：2
相关论文
共 50 条
  • [1] Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Sabbatini, Paul
    Dupont, Jakob
    Aghajanian, Carol
    Derosa, Felicia
    Poynor, Elizabeth
    Anderson, Sybil
    Hensley, Martee
    Livingston, Phillip
    Lasonos, Alexia
    Spriggs, David
    McGuire, William
    Reinartz, Silke
    Schneider, Sally
    Grande, Cathy
    Lele, Shashikant
    Rodabaugh, Kerry
    Kepner, James
    Ferrone, Soldano
    Odunsi, Kunle
    CLINICAL CANCER RESEARCH, 2006, 12 (18) : 5503 - 5510
  • [2] Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer
    Webber, Kate
    Friedlander, Michael
    BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY, 2017, 41 : 126 - 138
  • [3] Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer
    Hagemann, Andrea R.
    Novetsky, Akiva P.
    Zighelboim, Israel
    Gao, Feng
    Massad, L. Stewart
    Thaker, Premal H.
    Powell, Matthew A.
    Mutch, David G.
    Wright, Jason D.
    GYNECOLOGIC ONCOLOGY, 2013, 131 (03) : 535 - 540
  • [4] Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer
    Shih, K. K.
    Chi, D. S.
    Barakat, R. R.
    Leitao, M. M.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S104 - S104
  • [5] Beyond tertiary cytoreduction in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
    Shih, K. K.
    Chi, D. S.
    Barakat, R. R.
    Leitao, M. M., Jr.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : 364 - 369
  • [6] Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review
    Zagouri, Flora
    Sergentanis, Theodoros N.
    Chrysikos, Dimosthenis
    Dimopoulos, Meletios-Athanassios
    Bamias, Aristotle
    ONCOTARGETS AND THERAPY, 2015, 8 : 2187 - 2198
  • [7] Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    Kerliu, Lloreta
    Myruski, Samantha
    Bhatti, Afeefa
    Soni, Priyal
    Petrosius, Paulius
    Pervanas, Helen C.
    Horton, Evan R.
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (10) : 1010 - 1015
  • [8] PHASE I/II STUDY OF CARBOPLATIN AND PRALATREXATE IN PATIENTS WITH RECURRENT PLATINUM SENSITIVE OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER
    del Carmen, M.
    Campos, S.
    Krasner, C.
    Berlin, S.
    Supko, J.
    Atkinson, T.
    Birrer, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 419 - 420
  • [9] Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer
    Donald A. Richards
    David Loesch
    Svetislava J. Vukelja
    Hillary Wu
    William J. Hyman
    Jeffery Nieves
    Yunfei Wang
    Simin Hu
    Oluwatoyin O. Shonukan
    Datchen F. Tai
    Investigational New Drugs, 2011, 29 : 963 - 970
  • [10] Phase I study of pemetrexed and pegylated liposomal doxorubicin in patients with refractory breast, ovarian, primary peritoneal, or fallopian tube cancer
    Richards, Donald A.
    Loesch, David
    Vukelja, Svetislava J.
    Wu, Hillary
    Hyman, William J.
    Nieves, Jeffery
    Wang, Yunfei
    Hu, Simin
    Shonukan, Oluwatoyin O.
    Tai, Datchen F.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) : 963 - 970
12345